About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

TGRX-678 Phase I Oral Pharmacokinetic Study | Clinical Trials | Clareo Health

COMPLETEDPhase 1

TGRX-678 Phase I Oral Pharmacokinetic Study

Food Effect on Pharmacokinetic Profile for TGRX-678 Tablet in Chinese Healthy Subject With Single Oral Administration

NCT06697899•Shenzhen TargetRx Co., Ltd.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Chronic Myeloid Leukemia

Interventions

TGRX-678

Locations

1

China

Locations (1)

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

Key Dates

Start Date

November 24, 2024

Primary Completion Date

January 6, 2025

Completion Date

February 20, 2025

Last Updated

May 16, 2025

Related Studies

RECRUITINGPhase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+2 more

RECRUITINGPhase 1/2

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic Leukemia+6 more

RECRUITINGPhase 2

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

NCT06236724

Chronic Myeloid Leukemia

RECRUITINGPhase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Acute LeukemiaAcute Lymphoblastic Leukemia+17 more

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia+60 more

RECRUITINGPhase 1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773

Leukemia, Acute MyeloidMyelodysplastic Syndromes+6 more

View all related studies

Sponsors

Lead Sponsor

Shenzhen TargetRx Co., Ltd.

Collaborators

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions